Literature DB >> 31903478

Risk for Acromegaly-related Comorbidities by Sex in Korean Acromegaly.

Kyeong Hye Park1, Eun Jig Lee2, Gi Hyeon Seo3, Cheol Ryong Ku2.   

Abstract

CONTEXT: Reports on the incidence, characteristics, and comorbidity in Asian patients with acromegaly are scarce.
OBJECTIVE: To evaluate the incidence of acromegaly and the risk of comorbidities in East Asia, especially South Korea.
DESIGN: This nationwide population-based cohort study using the Korean Health Insurance Review and Assessment claims database evaluated the incidence of acromegaly, initially diagnosed from 2010 to 2013. We identified comorbidities during, before, and 2 years after diagnosis. Acromegaly and control cases (718 and 7180, respectively) were included in the analysis.
SETTING: A longitudinal case-control study using a nationwide population cohort.
RESULTS: The mean annual incidence rate of acromegaly was 3.57 cases per 1 000 000. Malignancies occurred in 61 patients with acromegaly (8.5%) during the study period and thyroid cancer was the most common malignancy (n = 38). In the acromegaly group, the overall risk of malignancy was higher: hazard ratio (HR), 2.82 (95% confidence interval [CI]: 2.12-3.74). Malignancy risk was more pronounced in females, with increased risk from the prediagnosis period that is sustained until the postdiagnosis period. Prevalence of diabetes mellitus (DM) and heart failure increased significantly in acromegalic patients. Over the entire period, DM developed in 51.1% and 57.0% of male and female acromegalic patients, respectively. Mortality risk was higher (HR 1.65, 95%; CI: 1.13-2.41) and statistically significant in females (HR 1.75, 95%; CI: 1.07-2.84).
CONCLUSION: Comorbidities associated with acromegaly differed by sex in Korean subjects. High malignancy and mortality risk should be considered in female patients when managing acromegaly in Korea. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  acromegaly; comorbidity; diabetes mellitus; incidence; malignancy; mortality

Year:  2020        PMID: 31903478     DOI: 10.1210/clinem/dgz317

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

Review 1.  Acromegaly and Colorectal Neoplasm: An Update.

Authors:  Leandro Kasuki; Bernardo Maia; Mônica R Gadelha
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-20       Impact factor: 6.055

Review 2.  Epidemiology of Functioning Pituitary Adenomas.

Authors:  Sang Ouk Chin
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

Review 3.  Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?

Authors:  Cheol Ryong Ku; Vladimir Melnikov; Zhaoyun Zhang; Eun Jig Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

4.  Clinical MEN-1 Among a Large Cohort of Patients With Acromegaly.

Authors:  Lisa B Nachtigall; Francisco J Guarda; Kate E Lines; Alireza Ghajar; Laura Dichtel; Giselle Mumbach; Wenxiu Zhao; Xun Zhang; Nicholas A Tritos; Brooke Swearingen; Karen K Miller; Rajesh V Thakker
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.